Purpose of the Screening
- Early detection of DiGeorge syndrome (22q11.2).
- Identifying risks of syndromes caused by chromosomal microdeletions.
- Providing accurate data for high-risk pregnancies without miscarriage risks.
Book cfDNA Microdeletion Screening | Lahalak Medical Platform
A safe and non-invasive screening that detects microdeletion syndromes in fetuses using maternal blood, providing early and accurate insights into your baby's genetic health with the latest NIPT technology.
Scientific name: Cell-Free DNA (cfDNA) Screening for Microdeletion Syndromes
A non-invasive prenatal test (NIPT) that analyzes fetal cell-free DNA to detect microdeletion syndromes, such as DiGeorge syndrome, ensuring early detection and specialized care for high-risk pregnancies.
Service type
Laboratory test
Duration
15-20 minutes
Fasting
Fasting is not required
Included Services
- Venous blood sample collection
- Cell-free fetal DNA analysis
- Detailed medical result report
Medical Service Information
Target Groups
- Pregnant women of advanced maternal age (over 35).
- Pregnancies classified as high-risk.
- Families with a history of genetic disorders.
Advantages of NIPT Technology
- Complete safety for both mother and fetus (non-invasive).
- Significantly higher accuracy compared to traditional screenings.
- Convenience of home collection services.
Conditions & Notices
- Test performed after the 10th week of pregnancy
- Recent ultrasound report is preferred to confirm gestational age
Medical services you might also like
